新型急诊脓毒症诊断试验的成本与后果:IntelliSep指数
该研究从美国医疗系统视角,在社区医院急诊科场景下构建决策树模型,比较IntelliSep指数(ISI)与降钙素原用于早期脓毒症诊断的成本与生存结局。假设脓毒症患病率为16.9%(经Sepsis-3裁定),ISI策略每例患者预期成本3849美元、预期生存率95.08%,而降钙素原策略预期成本4656美元、预期生存率94.98%。ISI成本更低且更有效,主要归因于假阴性结果更少,敏感性分析结果稳健。作者认为ISI可能为医疗系统提供更高价值的急诊脓毒症诊断试验,但需进一步在临床实践中验证。
要点
- 在脓毒症患病率16.9%(经Sepsis-3裁定)的假设下,ISI策略每例预期成本3849美元、预期生存率95.08%。
- 降钙素原策略每例预期成本4656美元、预期生存率94.98%,ISI成本更低且更有效。
- ISI的优势主要来自假阴性结果更少。
- 敏感性分析显示上述结果稳健。
- 作者认为ISI可能为医疗系统提供更高价值的急诊脓毒症诊断试验,但需进一步在临床实践中验证。
适用人群与场景
- 美国社区医院急诊科就诊、需早期脓毒症诊断的患者。
诊断标准与关键阈值
- 脓毒症患病率假设为16.9%,经Sepsis-3裁定。
研究设计与关键结果
- 研究类型为决策树分析,比较ISI与降钙素原用于急诊早期脓毒症诊断,模型参数包括脓毒症患病率、两种试验的敏感度和特异度、住院成本及按诊断试验结果分层的死亡率。
- 死亡率与脓毒症患病率取自现有最佳文献,成本基于大型全国出院数据集分析并调整为2018年美元。
- 假设脓毒症患病率16.9%(经Sepsis-3裁定),ISI策略每例患者预期成本3849美元、预期生存率95.08%。
- 降钙素原策略每例患者预期成本4656美元、预期生存率94.98%。
- ISI较降钙素原成本更低且更有效,主要因假阴性结果更少,敏感性分析结果稳健。
证据类型、等级与局限
- 证据类型:决策树分析(成本-后果分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ISI可能为医疗系统在急诊脓毒症评估中提供更高价值的诊断试验。
- 原文指出,尚需额外工作将这些结果在临床实践中验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Sepsis causes 270,000 deaths and costs $38 billion annually in the United States. Most cases of sepsis present in the emergency department (ED), where rapid diagnosis remains challenging. The IntelliSep Index (ISI) is a novel diagnostic test that analyzes characteristics of WBC structure and provides a reliable early signal for sepsis. This study performs a cost-consequence analysis of the ISI relative to procalcitonin for early sepsis diagnosis in the ED.
PERSPECTIVE: U.S. healthcare system.
SETTING: Community hospital ED.
METHODS: A decision tree analysis was performed comparing ISI with procalcitonin. Model parameters included prevalence of sepsis, sensitivity and specificity of diagnostic tests (both ISI and procalcitonin), costs of hospitalization, and mortality rate stratified by diagnostic test result. Mortality and prevalence of sepsis were estimated from best available literature. Costs were estimated based on an analysis of a large, national discharge dataset, and adjusted to 2018 U.S. dollars. Outcomes included expected costs and survival.
RESULTS: Assuming a confirmed sepsis prevalence of 16.9% (adjudicated to Sepsis-3), the ISI strategy had an expected cost per patient of $3,849 and expected survival rate of 95.08%, whereas the procalcitonin strategy had an expected cost of $4,656 per patient and an expected survival of 94.98%. ISI was both less costly and more effective than procalcitonin, primarily because of fewer false-negative results. These results were robust in sensitivity analyses.
CONCLUSIONS: ISI was both less costly and more effective in preventing mortality than procalcitonin, primarily because of fewer false-negative results. The ISI may provide health systems with a higher-value diagnostic test in ED sepsis evaluation. Additional work is needed to validate these results in clinical practice.
参考来源
- Hollenbeak CS, Henning DJ, Geeting GK, et al. Costs and Consequences of a Novel Emergency Department Sepsis Diagnostic Test: The IntelliSep Index. Crit Care Explor. 2023. PMID: 37465702. doi:10.1097/CCE.0000000000000942
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。